Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Shares Issued (2017 - 2018)

Crinetics Pharmaceuticals has reported Preferred Shares Issued over the past 2 years, most recently at $9000.0 for Q4 2018.

  • For Q4 2018, Preferred Shares Issued fell 99.92% year-over-year to $9000.0; the TTM value through Dec 2018 reached $63.3 million, changed N/A, while the annual FY2018 figure was $63.3 million, 427.29% up from the prior year.
  • Preferred Shares Issued for Q4 2018 was $9000.0 at Crinetics Pharmaceuticals, up from -$234000.0 in the prior quarter.
  • Over five years, Preferred Shares Issued peaked at $63.5 million in Q1 2018 and troughed at -$234000.0 in Q2 2018.